Methodology Devised to Improve Stem Cell Reprogramming
|
By LabMedica International staff writers Posted on 27 Jan 2015 |

Image: Induced pluripotent stem (iPS) cells, which act very much like embryonic stem cells, are shown growing into heart cells (blue) and nerve cells (green) (Photo courtesy of Gladstone Institutes/Chris Goodfellow).

Image: Microscopic view of a colony of induced pluripotent stem cells obtained by reprogramming a specialized cell for two weeks (Photo courtesy of UCLA Broad Stem Cell Research Center/Plath Lab).
In a study that provides scientists with a critical new determination of stem cell development and its role in disease, researchers have established a first-of-its-kind approach that outlines the stages by which specialized cells are reprogrammed into stem cells resembling those found in embryos. The research could have wide ranging, long-term implications in enhancing disease modeling and devising new therapies for patients.
The study, conducted by researchers from the University of California, Los Angeles (UCLA; USA) Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and led by Dr. Kathrin Plath, a professor of biological chemistry, was published January 2015 in the journal Cell. Induced pluripotent stem cells (iPSCs) are cells that can be generated from adult cells and then, like embryonic stem cells, be directed to become any cell in the human body. Adult cells can also be reprogrammed in the lab to change from a specialized cell back to an iPSC (and thereby becoming a cell similar to that of an embryonic stem cell).
Reprogramming takes one to two weeks and is a mostly inefficient process, with typically less than one percent of the beginning cells effectively becoming an iPSC. The exact stages a cell goes through during the reprogramming process are not well understood. This knowledge is vital, because iPSCs have great potential in the field of regenerative medicine, as they can constantly reproduce and provide a single source of patient-specific cells to replace those lost to injury or disease. They can also be used to create innovative disease models from which new drugs and therapies can be developed.
Vincent Pasque and Jason Tchieu, postdoctoral fellows in Plath’s lab and co-first authors of the study, developed a roadmap of the reprogramming process using detailed time-course analyses. They induced the reprogramming of specialized cells (that could only make more of themselves, and no other cell types), then observed and analyzed on a daily basis or every other day the process of transformation at the single-cell level. The data were gathered and recorded during a time period of up to two weeks.
Dr. Plath’s team found that the changes that happen in cells during reprogramming occur in sequentially, and that notably, the stages of the sequence were the same across the diverse reprogramming systems and different cell types analyzed. “The exact stage of reprogramming of any cell can now be determined,” Dr. Pasque said. “This study signals a big change in thinking, because it provides simple and efficient tools for scientists to study stem cell creation in a stage-by-stage manner. Most studies to date ignore the stages of reprogramming, but we can now seek to better understand the entire process on both a macro and micro level.”
Dr. Plath’s group additionally discovered that the stages of reprogramming to iPSC are different from what was expected. They found that it is not simply the reversed sequence of stages of embryo development. Some steps are reversed in the expected order; others do not actually happen in the exact reverse order and resist a change until late during reprogramming to iPSCs. “This reflects how cells do not like to change from one specialized cell type to another and resist a change in cell identity,” Dr. Pasque said. “Resistance to reprogramming also helps to explain why reprogramming takes place only in a very small proportion of the starting cells.”
With these findings, Dr. Plath’s lab plans future studies to actively isolate specific cell types during specific stages of reprogramming. They also hope the research will encourage further investigation into the characteristics of iPSC development. “This research has broad impact, because by understanding cell reprogramming better we have the potential to improve disease modeling and the generation of better sources of patient-specific specialized cells suitable for replacement therapy,” concluded Dr. Plath. “This can ultimately benefit patients with new and better treatments for a wide range of diseases.”
Related Links:
University of California, Los Angeles’ Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
The study, conducted by researchers from the University of California, Los Angeles (UCLA; USA) Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and led by Dr. Kathrin Plath, a professor of biological chemistry, was published January 2015 in the journal Cell. Induced pluripotent stem cells (iPSCs) are cells that can be generated from adult cells and then, like embryonic stem cells, be directed to become any cell in the human body. Adult cells can also be reprogrammed in the lab to change from a specialized cell back to an iPSC (and thereby becoming a cell similar to that of an embryonic stem cell).
Reprogramming takes one to two weeks and is a mostly inefficient process, with typically less than one percent of the beginning cells effectively becoming an iPSC. The exact stages a cell goes through during the reprogramming process are not well understood. This knowledge is vital, because iPSCs have great potential in the field of regenerative medicine, as they can constantly reproduce and provide a single source of patient-specific cells to replace those lost to injury or disease. They can also be used to create innovative disease models from which new drugs and therapies can be developed.
Vincent Pasque and Jason Tchieu, postdoctoral fellows in Plath’s lab and co-first authors of the study, developed a roadmap of the reprogramming process using detailed time-course analyses. They induced the reprogramming of specialized cells (that could only make more of themselves, and no other cell types), then observed and analyzed on a daily basis or every other day the process of transformation at the single-cell level. The data were gathered and recorded during a time period of up to two weeks.
Dr. Plath’s team found that the changes that happen in cells during reprogramming occur in sequentially, and that notably, the stages of the sequence were the same across the diverse reprogramming systems and different cell types analyzed. “The exact stage of reprogramming of any cell can now be determined,” Dr. Pasque said. “This study signals a big change in thinking, because it provides simple and efficient tools for scientists to study stem cell creation in a stage-by-stage manner. Most studies to date ignore the stages of reprogramming, but we can now seek to better understand the entire process on both a macro and micro level.”
Dr. Plath’s group additionally discovered that the stages of reprogramming to iPSC are different from what was expected. They found that it is not simply the reversed sequence of stages of embryo development. Some steps are reversed in the expected order; others do not actually happen in the exact reverse order and resist a change until late during reprogramming to iPSCs. “This reflects how cells do not like to change from one specialized cell type to another and resist a change in cell identity,” Dr. Pasque said. “Resistance to reprogramming also helps to explain why reprogramming takes place only in a very small proportion of the starting cells.”
With these findings, Dr. Plath’s lab plans future studies to actively isolate specific cell types during specific stages of reprogramming. They also hope the research will encourage further investigation into the characteristics of iPSC development. “This research has broad impact, because by understanding cell reprogramming better we have the potential to improve disease modeling and the generation of better sources of patient-specific specialized cells suitable for replacement therapy,” concluded Dr. Plath. “This can ultimately benefit patients with new and better treatments for a wide range of diseases.”
Related Links:
University of California, Los Angeles’ Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
Latest BioResearch News
- Blood NAD Levels May Offer Clues to Cardiovascular Health
- Organ-on-Chip System Offers Insights Into Tumor Interactions and Treatment Response
- Multiplexed Single-Cell DNA Methylation Workflow Enables Analysis of Blood Disorders
- Extracellular Vesicle Biomarkers Reveal Shared Signals in Aging and Cancer
- Study Reveals Regulatory DNA Element Involved in Breast Cancer Growth Suppression
- New ddPCR Assays Broaden Options for Multiplex Cancer Mutation Research
- Platelet Biomarkers Identify Progression Signals in Parkinson's Disease
- Molecular Atlas Offers New Framework for Breast Cancer Risk and Treatment Research
- New Method Isolates Neuron-Linked Vesicles From Blood and Cerebrospinal Fluid
- Lung Tumor RNA Variants Offer Clues to Immunotherapy Benefit
- Population-Scale Genome Survey Supports Interpretation of Genetic Testing
- Single-Cell Profiling Reveals Chemotherapy Resistance Signals in Ovarian Cancer
- Genomic Tool Supports Analysis of Repeat Expansions Linked to Inherited Disorders
- CSF Biomarker Meprin-Beta Increases in Alzheimer’s Disease
- Cancer DNA Trapping Mechanism Reveals Potential Target for Future Therapies
- Blood Antibody Signals May Offer Clues to the Origins of Childhood Cancer
Channels
Clinical Chemistry
view channel
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreMolecular Diagnostics
view channel
Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment
Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more
Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more
Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
Breast cancer screening can reduce mortality, but early detection remains challenging when tumors are small or difficult to identify through imaging. Blood-based liquid biopsies offer a potential complementary... Read more
Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
New WHO Tools Address Gaps in Antimicrobial Resistance Testing
Antimicrobial resistance (AMR) is a growing global health threat, making infections increasingly difficult to diagnose and treat as they become resistant to standard antibiotics. Its spread is driven partly... Read more
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians
Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







